CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Rhea-AI Summary
CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company specializing in bladder cancer therapeutics, has announced its upcoming participation at the TD Cowen 45th Annual Health Care Conference. Arthur Kuan, Chairman & Chief Executive Officer, will deliver a presentation in Boston, MA on March 5, 2025, at 11:10 am ET.
The presentation will be accessible via live audio webcast through the Investor Relations section of www.cgoncology.com. Following the live event, a replay will remain available for approximately 90 days on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – CGON
On the day this news was published, CGON gained 0.36%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from its innovative immunotherapies to live with dignity and have an enhanced quality of life.
Contacts
Media
Sarah Connors
VP, Communications and Patient Advocacy
(508) 654-2277
sarah.connors@cgoncology.com
Investor Relations
Chau Cheng
VP, Investor Relations
(949) 342-8939
chau.cheng@cgoncology.com
FAQ
When is CG Oncology (CGON) presenting at the TD Cowen Healthcare Conference 2025?
How can investors access CG Oncology's (CGON) TD Cowen conference presentation?
How long will CGON's TD Cowen conference presentation replay be available?
What is CG Oncology's (CGON) main therapeutic focus?
